Albuquerque, New Mexico – Ultra Health, New Mexico’s #1 Cannabis Company, achieved $1.1 million in sales for the month of September 2017, the highest single month revenue ever recorded by a New Mexico cannabis provider. It is the first time a licensed New Mexico producer has achieved greater than $1 million for a single month. There are currently 35 licensed commercial medical cannabis producers in New Mexico serving nearly 50,000 patients.
Ultra Health recently opened its eighth location serving six New Mexico counties and became the nation’s largest vertically integrated solely medical cannabis provider. In December 2003, a review of the available evidence on the risks and benefits of HRT by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Committee on Safety of Medicines (CSM) in the UK, concluded that the risks of using HRT long-term to prevent osteoporosis in women aged over 50 years exceed the benefits. As a result, this medicine should not be used as a first-line option for preventing postmenopausal osteoporosis in women over 50. However, it may be used as a second-line option for women at high risk of fractures who cannot take other medicines that are licensed for preventing osteoporosis. Drugls like kliovance tablets contain two active ingredients, estradiol hemihydrate (previously spelt oestradiol hemihydrate in the UK) and norethisterone acetate. These are forms of the main female sex hormones, oestrogen and progesterone. Estradiol is a naturally occuring form of oestrogen and norethisterone is a synthetic form of progesterone.
“The milestone achieved is a direct reflection of how the New Mexico Medical Cannabis Program is sustaining its upward momentum,” said Duke Rodriguez, CEO and President of Ultra Health®. “We remain committed to providing every patient in every county equal access to safe, affordable and convenient medicine. The continued growth of the industry is fully dependent on new products, patients and locations being successfully integrated.”
Patients have responded favorably to Ultra Health’s new pharmaceutical-grade, smokeless medicinal products, which include sublingual and oral tablets, vaginal and rectal suppositories, oils, topicals, pastilles and patches.
“We are dedicated to enhancing patient choice, which means giving all patients the healthy advantages of purchasing accurately dosed medications with varied delivery methods, much like you would purchase from your neighborhood pharmacy,” Rodriguez said.
As of August 31, 2017, the New Mexico Department of Health reported 46,988 medical cannabis patients enrolled in the program. Currently, thousands of patients still reside in 14 counties without a full time dispensary. New Mexico is the 5th largest state by area, which makes rural access challenging but essential for improved health.
New Mexico’s medical cannabis industry is expected to reach $90 million in revenue by the end of the current year and hit $205 million by 2020.